Author

S. T. Pals

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

M. Spaargaren· 2 shared A. Kuil· 1 shared C. J. van Noesel· 1 shared C. Maas· 1 shared E. E. Eldering· 1 shared F. Arenzana-Seisdedos· 1 shared G. de Wilde· 1 shared H. Lantermans· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Spaargaren

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivSep 29, 2020

The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma

Z. Ren, H. Lantermans, A. Kuil…·S. T. Pals

This study identifies CXCL12gamma as a membrane-bound chemokine that promotes multiple myeloma cell adhesion and drug resistance through interactions with heparan sulfate proteoglycans.

DOI 10.1186/s13045-021-01031-3

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivOct 24, 2019

Targeting AKT elicits tumor suppressive functions of FOXO transcription factors and GSK3 kinase in Multiple Myeloma

T. A. Bloedjes, G. de Wilde, C. Maas…·J. E. Guikema

This study shows that AKT inhibition in multiple myeloma activates FOXO and GSK3, leading to MCL1 reduction and cell death, suggesting potential for combination therapies.

DOI 10.1182/bloodadvances.2019001393

humanbulk RNA-seq

𝕏 PostBluesky